Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride is employed in ophthalmic practice to produce temporary mydriasis and cycloplegia for diagnostic and therapeutic purposes.

• Eye examinations: provides pupil dilation and accommodation paralysis to allow thorough retinal and anterior segment assessment.
• Diagnostic procedures: facilitates visualization of intra‑ocular structures during procedures such as fundoscopy and laser therapy.
• Uveitis management: used as an adjunct to improve examination conditions and reduce discomfort in inflammatory eye disease.

• Cyclopentolate Hydrochloride acts as a reversible competitive antagonist at muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By blocking these receptors, it prevents parasympathetic-mediated constriction of the pupil and accommodation, resulting in sustained mydriasis and cycloplegia that are useful for ocular examination and treatment.

Cyclopentolate ophthalmic solution may cause a range of ocular and systemic reactions.

Common Side Effects

• Stinging or burning sensation upon instillation
• Transient blurred vision
• Photophobia due to pupil dilation
• Mild headache
• Increased intra‑ocular pressure in susceptible eyes
• Mild conjunctival hyperemia

Serious or Rare Side Effects

• Acute angle‑closure glaucoma
• Systemic anticholinergic toxicity (confusion, tachycardia, dry mouth)
• Severe allergic reaction or anaphylaxis
• Persistent mydriasis lasting >24 hours
• Corneal edema or epithelial defect
• Vision loss secondary to ocular hypertension

Before using Cyclopentolate, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Assess intra‑ocular pressure: avoid in uncontrolled narrow‑angle glaucoma.
• Use with caution in children and the elderly: increased susceptibility to systemic anticholinergic effects.
• Avoid in patients with known hypersensitivity to cyclopentolate or other anticholinergics.
• Limit repeated dosing: prolonged exposure may exacerbate ocular hypertension.
• Administer only under professional supervision: ensure proper technique and dosage.
• Store at room temperature: keep in the original container, protect from light and moisture.

Cyclopentolate may interact with other medications that influence ocular dynamics or systemic anticholinergic load.

Major Interactions (Avoid)

• Systemic anticholinergic agents (e.g., antihistamines, tricyclic antidepressants): additive anticholinergic toxicity.
• Adrenergic agonist eye drops (e.g., phenylephrine): may reduce cyclopentolate‑induced mydriasis.

Moderate Interactions (Monitor Closely):\n- Topical beta‑blockers: potential impact on intra‑ocular pressure control.

• Other mydriatic agents: risk of excessive pupil dilation.
• CYP‑modulating drugs: although cyclopentolate is not extensively metabolised hepatically, monitor for unexpected systemic effects.